Rapport Therapeutics (NASDAQ:RAPP) Reaches New 1-Year High at $27.14

Rapport Therapeutics (NASDAQ:RAPP)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $27.14 and last traded at $25.43, with a volume of 217178 shares trading hands. The stock had previously closed at $23.84.

Analyst Ratings Changes

Several analysts have weighed in on RAPP shares. TD Cowen initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating for the company. Stifel Nicolaus assumed coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price target for the company. Finally, Jefferies Financial Group started coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price objective on the stock.

Rapport Therapeutics Trading Up 8.6 %

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, Director James Healy bought 44,032 shares of the business’s stock in a transaction on Monday, July 1st. The stock was purchased at an average cost of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the purchase, the director now directly owns 40,851 shares of the company’s stock, valued at $1,001,666.52. The acquisition was disclosed in a filing with the SEC, which is available at this link.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.